Catalog No: CFN99993

Evodiamine, a novel non-pungent vanilloid receptor agonist, which has the effects of anti-obese, analgesic, vasodilator, anti-oxidation, anti-inflammatory and anti-cancer. It prevents the accumulation of perivisceral fat and the body weight increase, blocks of the Ca2+ influx through receptor-mediated Ca2+ channels, inhibits NF-kB activation through suppression of IkB kinase activity.
Catalog No: CFN99998

Phillyrin is a novel AMPK activator, has anti-obesity effects in nutritive obesity mice, it can prevent lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1/AMPK activation. Phillyrin may be a new preventive agent of acute lung injury in the clinical setting, it potentially contributes to the suppression of the activation of MAPK and NF-κB pathways, it also has protective effects on H2O2-induced oxidative stress and apoptosis in PC12 cells.
Agrimol B
Catalog No: CFN98169

Agrimol B has antibacterial activity against Pseudomonas syringae pv. lacrymans (bacterial leaf spot pathogen), Ralstonia solanacearum (tomato bacterial wilt pathogen) and Pseudomonas syringae pv. tabaci (Tobacco wild fire pathogen). Agrimol B has a therapeutic potential on alleviating obesity, through modulation of SIRT1-PPARγ signal pathway.
Methyl orsellinate
Catalog No: CFN98406

Methyl orsellinate is a phytotoxic compound, it exhibits antifungal activity, it can cause significant inhibition of radicle growth of Amaranthus hypochondriacus and Echinochloa crus-galli, interact with bovine-brain calmodulin and inhibit the activation of the calmodulin-dependent enzyme cAMP phosphodiesterase. Methyl orsellinate can inhibit PTP1B activity with 50% inhibitory concentration values of 277 +/- 8.6 microM, the selective inhibition of PTP1B has been widely recognized as a potential drug target for the treatment of type 2 diabetes and obesity, methyl orsellinate may can treat the type 2 diabetes and obesity.
Catalog No: CFN98468

Norathyriol is a potent PTP1B inhibitor with good cell permeability and oral availability. Norathyriol as a safe new chemopreventive agent that is highly effective against development of UV-induced skin cancer. Norathyriol may be a dual, yet weak, cyclooxygenase and lipoxygenase pathway blocker, it has anti-inflammatory effect, and has inhibitory effect on the A23187-induced pleurisy and acetic acid-induced writhing response in mice. Norathyriol can relax the rat thoracic aorta mainly by suppressing the Ca2+ influx through both voltage-dependent and receptor-operated calcium channels. Norathyriol also can improve the glucose utilization and insulin sensitivity by up-regulation of the phosphorylation of AMPK.